Sangamo Therapeutics Statistics
Total Valuation
SGMO has a market cap or net worth of 68.36 million. The enterprise value is 60.10 million.
| Market Cap | 68.36M |
| Enterprise Value | 60.10M |
Important Dates
The next estimated earnings date is Thursday, August 13, 2026.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
SGMO has 414.29 million shares outstanding. The number of shares has increased by 52.37% in one year.
| Current Share Class | 414.29M |
| Shares Outstanding | 414.29M |
| Shares Change (YoY) | +52.37% |
| Shares Change (QoQ) | +15.36% |
| Owned by Insiders (%) | 0.93% |
| Owned by Institutions (%) | 16.44% |
| Float | 370.04M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.98 |
| PB Ratio | -3.61 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.74 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.70
| Current Ratio | 0.70 |
| Quick Ratio | 0.64 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.21 |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -94.37% |
| Return on Invested Capital (ROIC) | -457.25% |
| Return on Capital Employed (ROCE) | -1,615.02% |
| Weighted Average Cost of Capital (WACC) | 8.86% |
| Revenue Per Employee | 243,359 |
| Profits Per Employee | -868,521 |
| Employee Count | 142 |
| Asset Turnover | 0.47 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -687,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -65.38% in the last 52 weeks. The beta is 1.29, so SGMO's price volatility has been higher than the market average.
| Beta (5Y) | 1.29 |
| 52-Week Price Change | -65.38% |
| 50-Day Moving Average | 0.19 |
| 200-Day Moving Average | 0.40 |
| Relative Strength Index (RSI) | 47.28 |
| Average Volume (20 Days) | 3,198,009 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.53 |
Income Statement
In the last 12 months, SGMO had revenue of 34.56 million and -123.33 million in losses. Loss per share was -0.38.
| Revenue | 34.56M |
| Gross Profit | -78.68M |
| Operating Income | -110.32M |
| Pretax Income | -124.02M |
| Net Income | -123.33M |
| EBITDA | -106.66M |
| EBIT | -110.32M |
| Loss Per Share | -0.38 |
Balance Sheet
The company has 27.59 million in cash and 19.33 million in debt, with a net cash position of 8.25 million or 0.02 per share.
| Cash & Cash Equivalents | 27.59M |
| Total Debt | 19.33M |
| Net Cash | 8.25M |
| Net Cash Per Share | 0.02 |
| Equity (Book Value) | -18.96M |
| Book Value Per Share | -0.05 |
| Working Capital | -16.02M |
Cash Flow
In the last 12 months, operating cash flow was -90.34 million and capital expenditures -115,000, giving a free cash flow of -90.46 million.
| Operating Cash Flow | -90.34M |
| Capital Expenditures | -115,000 |
| Depreciation & Amortization | 3.66M |
| Net Borrowing | n/a |
| Free Cash Flow | -90.46M |
| FCF Per Share | -0.22 |
Margins
| Gross Margin | -227.67% |
| Operating Margin | -319.25% |
| Pretax Margin | -358.88% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SGMO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -52.37% |
| Shareholder Yield | -52.37% |
| Earnings Yield | -180.42% |
| FCF Yield | -132.33% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for SGMO is 1.67, which is 882.35% higher than the current price. The consensus rating is "Buy".
| Price Target | 1.67 |
| Price Target Difference | 882.35% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 90.76% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
SGMO has an Altman Z-Score of -43.38 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -43.38 |
| Piotroski F-Score | 1 |